Mitoquinone (MitoQ) |
Catalog No.GC30416
One-Click Copy Product Info
|
Mitoquinone (MitoQ) est un antioxydant dérivé de l'ubiquinone qui peut se lier de manière covalente à un cation triphénylphosphonium (TPP) lipophile, ciblant spécifiquement les mitochondries.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 444890-41-9
Sample solution is provided at 25 µL, 10mM.
- Ecotox Environ Safe 264 (2023):115459.PMID:37703808
- Int Immunopharmacol 130 (2024):111682.PMID:38394885
- J Agr Food Chem 70.42 (2022):13765-13777.PMID:36239691
- Iscience (2025).
- Neuroscience (2023).PMID:37290684
- Exp Gerontol 189 (2024):112402.PMID:38484905
- Comp Biochem Phys C (2024):109942.PMID:38810896
- Sci Rep-Uk 14.1 (2024):26504.PMID:39489819
- Sci Rep-Uk 14.1 (2024):26504.PMID:39489819
- Iscience 28.5 (2025).PMID:40330887
- Exp Physiol (2025).PMID:40163698
- Iran J Public Health 53.3 (2024):614-624.
- Anim Reprod Sci 247 (2022):107099.PMID:36306716
- Heliyon (2024).
- Nat Rev Mol Cell Bio 13.9 (2024) 653:
Mitoquinone (MitoQ) est un antioxydant dérivé de l'ubiquinone qui peut se lier de manière covalente à un cation triphénylphosphonium (TPP) lipophile, ciblant spécifiquement les mitochondries. MitoQ est généralement stocké dans les mitochondries in vivo afin de prévenir et de protéger les dommages cellulaires induits par la surproduction de ROS mitochondriaux et le stress oxydatif.
Lors d'une expérience in vitro, il a été démontré que les plaquettes lavées incubées avec 10 µM de MitoQ (4,8 % ± 0,8 %) augmentaient de manière marquée la population calcein-négative (effet cytotoxique) par rapport à un groupe témoin non traité ; 10 μM de MitoQ (8,5 % ± 2,2 %) induisaient une augmentation significative de l'exposition de la PS sur la membrane des plaquettes par rapport au contrôle basal. De plus, MitoQ (5 μM) a inhibé l'agrégation plaquettaire induite par le collagène et l'ADP dans des échantillons de PRP. Par ailleurs, MitoQ à 2,5 et 5 μM a produit une diminution évidente de la production de ROS générée par l'antimycine A ou le collagène sur les plaquettes.
In vivo, un traitement avec 2,5 mg/kg et 5 mg/kg de MitoQ peut atténuer les changements histologiques pulmonaires induits chez la souris par la fumée de cigarette (CS). Une expérience in vivo a montré qu'un traitement à la mitoquinone de 10 mg/kg/jour par gavage pendant 4 semaines améliorait visiblement la structure hépatique en association avec une diminution significative du dépôt de collagène. Par ailleurs, le traitement à la mitoquinone a déterminé une réduction significative de l'inflammation hépatique et de la fibrose. De plus, les expressions géniques de TIMP-1, MMP-2 et MMP-13 ont été réduites par le traitement à la Mitoquinone.
References:
[1]. Yang D, et al. Mitoquinone ameliorates cigarette smoke-induced airway inflammation and mucus hypersecretion in mice. Int Immunopharmacol. 2021 Jan;90:107149.
[2]. Chen W, et al. Inhibition of Mitochondrial ROS by MitoQ Alleviates White Matter Injury and Improves Outcomes after Intracerebral Haemorrhage in Mice. Oxid Med Cell Longev. 2020 Jan 4;2020:8285065.
[3]. Méndez D, et al. Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192.
[4]. Turkseven S, et al. Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G298-G304.
| Expériences cellulaires [1]: | |
Lignées cellulaires | Fibroblastes embryonnaires de souris (MEF) |
Méthode de préparation | Les cellules ont été traitées avec MitoQ pendant 16 h. L’anion superoxyde a été déterminé en incubant les cellules avec 50 nM MitoSox pendant 30 min. Pour analyser l’effet de MitoQ à 0,05 et 0,1 µM sur le stress oxydatif aigu, les cellules MEFwt ont été incubées avec MitoSox en l’absence ou en présence de 5 µM antimycin A. |
Conditions de réaction | 0,05 et 0,1 µM, 16h |
Domaines d'application | MitoQ à 2,5 et 5 μM a produit une diminution significative de la production de ROS générée par l'antimycine A ou le collagène sur les plaquettes. |
| Expériences animales [2]: | |
Modèles animaux | Rats mâles Sprague-Dawley |
Méthode de préparation | L’administration de Mitoquinone (10 mg•kg−1•jour−1 ; MitoQ, Nouvelle-Zélande ; n = 10) ou de véhicule (diméthylsulfoxyde 0,7 % ; n = 10) par gavage a commencé 3 jours après CBDL et a continué pendant 4 semaines. Trois heures après la dernière administration, les rats ont été euthanasiés. |
Forme de dosage | 10 mg•kg−1•jour−1, p.o. |
Domaines d'application | Le poids des foies des rats traités avec la mitoquinone était significativement plus bas que celui des foies des animaux cirrhotiques non traités et similaire à celui des contrôles, probablement en raison de la réduction de l’inflammation hépatique. |
Références : [1]. Méndez D, et al. Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192 [2]. Turkseven S, et al. Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2). | |
| Cas No. | 444890-41-9 | SDF | |
| Canonical SMILES | O=C(C(CCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=C4C)C(OC)=C(OC)C4=O | ||
| Formula | C37H44O4P | M.Wt | 583.72 |
| Solubility | DMSO : 50 mg/mL (73.66 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7132 mL | 8.5658 mL | 17.1315 mL |
| 5 mM | 342.6 μL | 1.7132 mL | 3.4263 mL |
| 10 mM | 171.3 μL | 856.6 μL | 1.7132 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: An oil
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
TK-MLP@(GP+EM) NPs can restore endothelial function in ApoE−/−atherosclerosis mice. (A)Aortic root cross-sections were subjected to dihydroethidium staining for determination of the redox state with quantitative analysis of DHE MFI.
The interventions included intravenous administration of saline, Mitoquinone (MitoQ)(GlpBio, USA) at a dosage of 5mg/kg, a combination of GP+EM at a dosage of 5mg/kg GP and 5mg/kg EM, and TK-MLP@(GP+EM) NPs at a dosage of 5mg/kg GP and 5mg/kg EM.
Journal of Nanobiotechnology 22.1 (2024): 129. PMID: 38528554 IF: 10.2 -
Related Biological Data
MitoQ attenuated ERS and ERS-dependent apoptosis by alleviating mitochondrial oxidative damage in HepG2 cells exposed to HFPO-TA. (A) Cell viability of HepG2 cells exposed to 75μM HFPO-TA and/or 5μM MitoQ for 24h. HepG2 cells were pretreated with 5μM MitoQ for 30min.
HepG2 cells were pretreated with 50μM 2-APB and 5μM MitoQ(GlpBio, USA) for 1h and 30min, respectively, followed by exposure to 75μM HFPO-TA for 24h.
Sci Total Environ (2024): 171234. PMID: 38428612 IF: 9.8003 -
Related Biological Data
MitoQ attenuated mitochondrial damage and hippocampal injury in AlCl3-treated Parkin-/- mice. (F) Effect of MitoQ on the structure of the hippocampus of mice was observed by observing the microstructure of CA1 and CA3 regions. Yellow arrows indicated degenerated necrotic cells.
The second-time was treated with normal saline, MitoQ(GlpBio, USA)(5mg/kg body weight, twice weekly) or MCC950 (10mg/kg body weight, twice weekly) by intraperitoneal injection in the afternoon of the same day.
iScience.2021 Sep 25;24(10):103170. PMID: 37703808 IF: 6.7996 -
Related Biological Data
MitoQ alleviated mtROS overproduction, activation of NLRP3-inflammasome and W/β signaling and fibrosis in the T-2 cell model. (L) Cell viability of HK-2 cell.
MitoQ (mtROS scavenger) was given to mice by the intraperitoneal injection28 (GLPBIO, USA, 5mg/kg, twice weekly for 4 weeks).
J Agr Food Chem (2022). PMID: 36239691 IF: 5.8954 -
Related Biological Data
(C) DHE staining of mtROS (magnification, 400 × ).
The MitoQ (mtROS scavenger; GLPBIO, USA) was intraperitoneally administered to mice in HFPO-TA + MitoQ group (5 mg/kg, twice/week for 4 weeks).
Food Chem Toxicol (2023): 113706. PMID: 36871880 IF: 5.5716 -
Related Biological Data
Levels of lactate dehydrogenase (LDH) released from aged hearts following IR injury. Data were analyzed using one-way ANOVA followed by Tukey’s post hoc test, and presented as Mean ± SEM.
Treatment groups were received 100mg/kg/day ALA by oral gavage or 10 mg/kg/day MitoQ (GC30416, purity 98%, GLPBIO Technology, USA) by intraperitoneal injection for 14 consecutive days [25–27] before induction of ischemia.
Heliyon (2024). PMID: 38524576 IF: 4.0000
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)